Introduction PTEN (a.k.a. MMAC1 and TEP) is a recently identi®ed tumor suppressor gene located on human chromosome 10q23.3 (Li and Sun, 1997; Steck et al., 1997) . Deletions and mutations in PTEN occur frequently in advanced cancers including breast cancer, glioblastoma multiforme, endometrial carcinoma, malignant melanoma, bladder carcinoma, small cell lung cancer, and endometrioid ovarian cancer (Parsons, 1998; Teng et al., 1997) . Germ-line mutations of PTEN are the cause of Cowden's and BannayanZonana breast cancer predisposition syndromes, conditions in which 80 per cent of the associated tumors that arise are breast cancers Marsh et al., 1997) . PTEN is also required for embryogenesis, but embryonic stem cells lacking functional PTEN have greater tumorigenic capability and heterozygous PTEN`knockout' mice manifest the bowel hamartomas characteristic of Cowden's syndrome as well as an increased propensity for tumor development (Di Cristofano et al., 1998; Suzuki et al., 1998; Podsypanina et al., 1999) PTEN encodes a 403-amino-acid phosphatase capable of dephosphorylating phosphorylated serine, threonine and tyrosine residues (Myers et al., 1997) . PTEN interacts with the focal adhesion kinase (FAK) and, by virtue of its protein tyrosine phosphatase activity, PTEN reduces FAK phosphorylation and activity so as to alter cell adhesion, spreading and migration (Tamura et al., 1998 . Importantly, PTEN also has the ability to dephosphorylate position D3 of phosphatidylinositol (3,4,5) trisphosphate, the latter of which represents a direct product of phosphatidylinositol 3-kinase (PI3K) activity (Maehama and Dixon, 1998) . Strikingly, a number of germline and sporadic mutations in PTEN, such as the substitution of glutamic acid for the glycine residue at position 129 (G129E), ablate the ability of PTEN to dephosphorylate phosphatidylinositol (3,4,5) trisphosphate, but leave PTEN protein phosphatase activity intact (Furnari et al., 1998; Myers et al., 1997 Myers et al., , 1998 . The association of these mutations with cancer, combined with the capacity of the G129E mutated form of PTEN to dephosphorylate FAK and regulate cell spreading in a fashion indistinguishable from wildtype PTEN (Tamura et al., 1998) , indicates that dephosphorylation of phosphatidylinositol (3, 4, 5) trisphosphate represents a function of PTEN critical to this protein's, ability to act as a tumor suppressor.
Enforced expression of PTEN has been reported to result in decreased cell proliferation and decreased tumorigenicity (Cheney et al., 1998 (Cheney et al., , 1999 Furnari et al., 1998; Li and Sun, 1998; Tamura et al., 1999; Tian et al., 1999) , an observation attributed to the ability of PTEN to induce cell cycle arrest, apoptosis or anoikis, a form of apoptosis that occurs when cells are dissociated from their extracellular matrix (Davies et al., 1998 (Davies et al., , 1999 Frisch and Ruoslahti, 1997; Furnari et al., 1998; Li and Sun, 1998; Sun et al., 1999; Ramaswamy et al., 1999; Stambolic et al., 1998) . However, a consensus has not been reached on whether the capacity of PTEN to modulate these processes is determined by cell lineage or culture conditions. Similarly, the biochemical mechanisms whereby PTEN in¯uences cell behavior are not well understood. However, enforced expression of PTEN has been linked to the decreased phosphorylation or activity of AKT, BAD and 4E-BP1 proteins, which act downstream of PI3K in various signaling cascades (Datta et al., 1997; Davies et al., 1998 Davies et al., , 1999 Delcommenne et al., 1998; Haas-Kogan et al., 1998; Pap and Cooper, 1998; Wu et al., 1998; Tian et al., 1999; Ramaswamy et al., 1999) and increased expression of p27, which is also downstream of PI3K (Cheney et al., 1999; Sun et al., 1999) .
In view of the central role for PTEN in the Cowden's breast cancer predisposition syndrome and its frequent mutation in breast cancers, we have investigated the ability of PTEN to regulate signaling and biological functions of breast cancer cells. We report, herein, that PTEN downregulates PI3K-dependent phosphorylation and the activation of diverse downstream targets of the PI3K signaling cascade. This inhibitory eect of PTEN requires an intact phosphatase domain. When overexpressed in breast cancer cells, PTEN can inhibit cell cycle progression, induce apoptosis and accelerate anoikis, but these properties of PTEN are modulated by the activity of growth factors present in serum as well as concomitant anchorage-dependent cell activation, for example through ligation of integrin receptors. These data also indicate the eects of PTEN on cell cycle progression and cell death to be attributable, at least in part, to its ability to alter phosphorylation of the AKT, p70S6 kinase, BAD and GSK3 apoptotic mediators and expression of the p27Kip1 cell cycle regulator.
Results

PTEN regulates duration of signaling through PI3K
PTEN has the potential to function as an antagonist of PI3K-dependent signaling in breast cancer cells . To address this possibility, PI3K-dependent signaling was investigated in breast cancer cell lines with and without PTEN mutations. As shown in Figure  1 , PTEN protein was not detected in two breast cancer cell lines, MDA-MB-468 and BT-549, which carry deletion and frame shift mutations at codons 70 and 274, respectively . By contrast, the SKBr3, MCF7 and MDA-MB-231 breast cancer cell lines express similar amounts of PTEN as do normal breast epithelium (NB018) and the immortalized normal breast epithelial cell lines, MCF10A and MCF10F compatible with a lack of PTEN sequence abnormality in SKBr3, MCF7 and MDA-MB-231 . As shown in Figure 2A , breast cancer cells expressing mutant PTEN (MDA-MB-468 and BT-549) display higher levels of basal (time 0) AKT phosphorylation, indicative of increased PI3K signaling, than do cells expressing wild-type PTEN (SKBr3 and MDA-MB-231). EGF induced marked increases in AKT phosphorylation in the MDA-MB-468, SKBr3 and MDA-MB-231 cells (Figure 2A ). In BT-549 cells, EGF induced modest, if any, eects on AKT phosphorylation, an observation which may re¯ect the high basal levels of AKT phosphorylation in these cells (Figure 2A) . Strikingly, the duration of EGF-induced AKT phosphorylation was markedly increased in cells with mutant PTEN (MDA-MB-468), with levels of AKT phosphorylation remaining increased at 4 h after activation. By contrast, AKT phosphorylation declined in SKBr3 and MDA-MB-231 cells by 1 h after activation and returned to basal levels by 4 h.
To con®rm that the high basal and prolonged duration of AKT phosphorylation in MDA-MB-468 cells was due to mutations in PTEN and not due to overexpression of the EGFR (Bates et al., 1990) , wildtype PTEN was reintroduced into these cells and its eects on AKT phosphorylation was examined. As indicated in Figure 2B , introduction of wild-type PTEN resulted in a marked decrease in basal phosphorylation and in the duration of ligand-induced phosphorylation of co-transfected AKT. The eect of PTEN on AKT phosphorylation persisted for at least 48 h in the presence or absence of serum (not presented). The effect of PTEN on AKT phosphorylation required the phosphatase activity of PTEN, as no dierences were detected between the eects of a vector control and those observed using a mutated form of PTEN (PTEN C124S), which ablates both protein and lipid phosphatase activity ( Figure 2B ). PTEN lipid phosphatase activity was also critical to the kinetics of AKT phosphorylation as AKT phosphorylation was not altered by a mutated form of PTEN (PTEN G129E) ( Figure 2B ) in which phosphatidyinositol 3' phosphatase activity of PTEN is lost, but protein phosphatase activity remains intact (Funari et al., 1998; Myers et al., 1998) (Figure 2B ).
PTEN regulates phosphorylation of multiple components of the PI3K signaling cascade
As indicated by the immunoblotting data shown in Figure 3 , introduction of wild-type PTEN, but not catalytically inactive PTEN (C124S), into BT-549 and MDA-MB-468 cells, resulted in marked decreases in the phosphorylation of multiple downstream components of Figure 1 Expression of PTEN in breast cell lines. Endogenous PTEN was immunoprecipitated from 500 mg of cellular protein using goat anti-PTEN, separated by 8% SDS ± PAGE and immunoblotted with rabbit anti-PTEN the PI3K signaling cascade, including AKT (serine 473), BAD (serine 112 and serine 136), GSK3a (serine 21) and p70S6 kinase (serine 411, threonine 421 and serine 424). Thus PTEN appears to modulate a number of phosphorylation events known to be relevant to the functions of these PI3K pathway components (Coer et al., 1998; Pullen and Thomas, 1997) . With each of these eectors, PTEN was found to be more eective at decreasing basal than at decreasing fetal bovine serum or EGF-stimulated levels of phosphorylation. Similar eects on basal phosphorylation were observed in the context of both plasmid and adenoviral-mediated PTEN expression and also through the use of the relatively speci®c PI3K inhibitor, wortmannin. By contrast, ligand-induced phosphorylation was more eciently reversed by wortmannin treatment than by PTEN overexpression (Figure 3 ). Both rapamycin and wortmannin also decreased p70S6 kinase phosphorylation, a result consistent with data placing the p70S6 kinase downstream of PI3K and the rapamycin-sensitive FRAP/TOR PI3K superfamily member (Chou and Blenis, 1995) . Strikingly, overexpression of PTEN in breast cancer cells containing wild-type PTEN (SKBr3 and MCF-7) did not alter either basal or induced AKT phosphorylation ( Figure 3D ). This result was in marked contrast to that detected in wortmannin treated cells, in which phosphorylation was eectively suppressed independent of the presence or absence of functional PTEN (Figure 3 ). These data suggest that PTEN levels are not limiting in these cell lines and raise the possibility that induced PTEN overexpression may markedly in¯uence tumor cells while having limited eects on normal cells. Taken together, these results indicate that PTEN acts to suppress basal activity of the PI3K pathway but has a much less signi®cant eect on ligand-induced PI3K signaling. The data also suggest (C124S) or lipid phosphatase inactive but protein phosphatase competent PTEN (G129E). Cell lysates were immunoprecipitated with anti-HA, separated by 8% SDS ± PAGE and immunoblotted with anti-phospho-AKT (Ser473) and reprobed with anti-AKT to con®rm equal loading and equivalent transfections. PTEN expression was assessed by immunoprecipitation with anti-FLAG (M2) and immunoblotting with rabbit anti-PTEN that PTEN activity is, in the same manner, suppressed in conjunction with ligand evoked PI3K signaling.
PTEN increases expression of p27Kip1
As indicated in Figure 4A ,B, expression of PTEN in BT-549 or MDA-MB-468 was also associated with increased expression of the p27Kip1 cyclin dependent kinase inhibitor. In contrast to the data shown in Figure 3 , the eects of PTEN on p27Kip1 are most clearly manifested in the presence of ligand, possibly re¯ecting the fact that p27Kip1 expression levels are lower in stimulated than unstimulated cells (Figure 4) . In contrast, under the same conditions, PTEN only modestly downregulates expression of the p53-dependent cyclin dependent kinase inhibitor, p21Cip1/Waf1 (data not shown).
PTEN inhibits cell proliferation
The data concerning PTEN eects on p27Kip1 expression and on phosphorylation of AKT, BAD, GSK3a and p70S6K raised the possibility that PTEN expression in BT-549 or MDA-MB-468 might alter cell cycle progression as well as cell sensitivity to apoptosis. As indicated in Figure 5 , expression of PTEN in BT-549 or MDA-MB-468 cells resulted in lower proliferation rates (as indicated by MTT dye conversion) than those detected in mock infected or empty virus (DE1) infected cells in the presence of high (10%) or low (0.5%) fetal bovine serum. This eect of PTEN on cell proliferation was similar to that induced by LY294002, a PI3K inhibitor, utilized in these studies due to its decreased toxicity compared to wortmannin (the LY294002 concentrations used are equally as eective as wortmannin at inhibiting PI3K, data not presented). As is consistent with the lack of PTEN eect on AKT phosphorylation in cells containing intact PTEN (Figure 3) , expression of PTEN did not decrease the proliferation of T47D breast cancer cells expressing wild-type PTEN (not presented).
PTEN alters cell cycle progression, apoptosis and anoikis dependent on culture conditions
The association of PTEN expression with reduced proliferation of MDA-MB-468 and BT-549 cells ( Figure 5 ) may re¯ect cell cycle arrest and/or an increase in the fraction of cells undergoing apoptotic cell death. Under anchorage dependent conditions, in which integrins may be ligated by extracellular matrix components (Frisch and Ruoslahti, 1997) and in the presence of high concentrations of serum, expression of PTEN was found to be associated with increases in the percentage of MDA-MB-468 cells ( Figure 6 and Table  1 ) and BT-549 cells (not presented) in the G1 phase of the cell cycle, a result indicative of cell cycle arrest. This observation is compatible with the detection of increased P27Kip1 expression in these cells following introduction of PTEN (Figure 4 ). PTEN did not induce apoptosis under anchorage-dependent conditions in the presence of high serum (10%), as indicated by the results of propidium iodide staining (Figure 6 ), a TdT-based apoptosis assay ( Figure 7A ) and by exposure of the Apo 2.7 apoptosis-related mitochondrial protein (Table 2 . Koester et al., 1997; Pepper et al., 1998) . These ®ndings are consistent with the data revealing the eects of serum on phosphorylation of the AKT, p70S6 kinase, GSK3a and BAD apoptotic regulators to be only partially antagonized by introduction of PTEN ( Figure 3) ; and the eects of serum on the RAS/MAPK pathway, which can prevent apoptosis (Xia et al., 1995; Downward, 1998; Werner and Le Roith, 1997) , to be completely resistant to the eects of PTEN (not presented, Davies et al., 1998) .
As illustrated by the data shown in Figure 3 , the eects of PTEN on signaling through the PI3K pathway are most clearly manifest in the absence of serum. Strikingly, when BT-549 and MDA-MB-468 cells were cultured under anchorage dependent conditions in the presence of limiting concentrations of serum (0.5%), the cells underwent a signi®cant degree of apoptosis as assessed by DNA fragmentation and exposure of the Apo 2.7 antigen ( Figure 7A , Table  2 ). The PI3K inhibitors, LY294002 and wortmannin ( Figure 7A ), also induced increased apoptosis under these conditions, an observation consistent with the capacity of PTEN expression to decrease signaling through the PI3K pathway.
The PI3K pathway has been implicated in the prevention of anoikis, a form of apoptosis initiated by disruption of interactions between transmembrane integrins and ligands in the extracellular matrix (Frisch and Ruoslahti, 1997; Howe et al., 1998) . BT-549 and MDA-MB-468 cells were cultured under anoikis conditions (inability to adhere to plastic due to rocking), expression of PTEN induced an increased rate of anoikis in the presence of high concentrations of serum as indicated by the presence of free DNA ends ( Figure 7B ) and by PARP cleavage (not presented). The eect of PTEN on anoikis, as on apoptosis, was most marked, however, when cells were cultured in the presence of low concentrations of serum (0.5%). Thus, PTEN modulates cell cycle progression, apoptosis and anoikis and its eects on those facets of cell behavior depend upon cell culture conditions, factors present in serum as well as integrin ligation.
Breast cancer cells with mutant PTEN are more sensitive to the growth inhibitory eects of PI3K inhibitors
As noted above, the eects of PTEN on signaling and cell proliferation are most clearly manifest in cells that lack functional PTEN. In addition, inhibitors of PI3K exert similar eects on the PI3K signaling cascade as does enforced PTEN expression in cells lacking functional PTEN (Figure 3 ). As indicated in Figures  5 and 7 , the speci®c PI3K inhibitor LY294002 decreases proliferation and induced apoptosis and anoikis in BT-549 and MDA-MB-468 cells. In this context, the eect of LY294002 on the proliferation of breast cancer cells containing normal or mutant PTEN was also examined. As the IC50 for LY294002 for puri®ed PI3K activity is 1.44 mM (Vlahos et al., 1994) , these studies were carried out using 1 mM LY294002. As indicated in Figure 8 , cells which lack PTEN (BT-549 and MDA-MB-468) were markedly more sensitive to the growth inhibitory eects of LY294002 than were cells expressing functional PTEN (SKBr3 or MDA-MB-231). Together, these observations suggest that molecular therapeutics aimed at inhibiting the PI3K pathway may be particularly ecacious in breast cancer cells lacking functional PTEN.
Discussion
In the current study, we have shown that breast cancer cells lacking PTEN protein demonstrate increased basal levels of PI3K activity and markedly increased duration of ligand-induced PI3K signaling. These ®ndings suggest a role for PTEN in inhibiting both constitutive and ligand-induced PI3K signaling. This eect of PTEN is dependent on its phosphatase activity and more speci®cally on its lipid phosphatase activity as PI3K signaling is not in¯uenced by the C124S and G129E mutant forms of PTEN, which ablate total phosphatase activity and only lipid phosphatase activity, respectively. While both PTEN and the PI3K inhibitor wortmannin decreased basal phosphorylation of AKT, wortmannin blocked ligandinduced AKT phosphorylation as eciently as basal AKT phosphorylation. By contrast, PTEN had little eect on the magnitude of ligand-induced PI3K signaling. In breast cancer cells expressing functional PTEN protein, induced expression of additional PTEN did not alter basal or ligand-induced PI3K signaling (Figure 3 ). Taken together, these data suggest that PTEN is active constitutively and that its activity following cellular stimulation is constrained by an as of yet unknown mechanism so as to facilitate signaling through the PI3K pathway. Signal transduction may then be terminated, at least in part, by a subsequent return of PTEN activity to basal (high) levels. As PTEN dephosphorylates membrane phosphatidylinositols, this restoration of PTEN activity may re¯ect recruitment of PTEN to the membrane and/or changes in PTEN speci®c activity.
Considerable controversy exists as to the eects of PTEN on cell proliferation, viability and anoikis (Cheney et al., 1998 (Cheney et al., , 1999 Davies et al., 1998 Davies et al., , 1999 Furnari et al., 1997 Furnari et al., , 1998 Li and Sun, 1998; Stambolic et al., 1998; Podsypanina et al., 1999; Ramaswamy et al., 1999; Sun et al., 1999; Tian et al., 1999 ). In the current study, induced expression of PTEN in PTEN de®cient breast cancer cells, was associated with a marked decrease in the basal phosphorylation of AKT, p70S6 kinase, BAD, and GSK3a, alterations indicative of decreased activity and signaling through the PI3K pathway. However, the eects of PTEN expression on ligandinduced activation of these molecules were limited. As AKT, BAD, p70S6 kinase and GSK3a have all been implicated in the regulation of apoptosis (Cardone et al., 1998; Datta et al., 1997; Delcommenne et al., 1998; Li and Sun, 1998; Pap and Cooper, 1998; Shi et al., 1995) , these data suggest that expression of PTEN in the absence of exogenous ligand predisposes cells to undergo apoptosis. Further, expression of PTEN did not alter ligand-induced phosphorylation of erk2 indicative of intact signaling through the RAS-MAPK cascade which can prevent apoptosis (Xia et al., 1995; Werner and Le Roith, 1997; Downward, 1998) . These observations may contribute to the ®nding that PTEN expression induces cellular apoptosis under low serum culture conditions, but not in the context of high serum concentrations (Figure 7 ). By contrast, the eects of PTEN on expression of the p27Kip1 CDK inhibitor was most clearly manifest in the presence of high serum concentrations (Figure 4) and, under these culture conditions, PTEN induced a partial G1 arrest ( Figure  6 and Table 1 ). In the presence of serum, where cell survival is mediated by ligand dependent activation of the PI3K pathway or of the RAS/MAPK cascade (Figures 2 and 3) , the increased expression of p27Kip1 is likely sucient to mediate the partial growth arrest. Taken together, these data suggest that the growth inhibition engendered by PTEN re¯ects induction of both cell cycle arrest and apoptosis. Whether the dierential eects of PTEN on basal versus ligandinduced signaling accounts for the disparities in the literature in relation to observed eects of PTEN on cell cycle progression and apoptosis remains to be determined. However, as previous studies of PTEN eects on cell cycle progression and apoptosis have utilized multiple dierent cell lineages and cell lines, the variability in study results may also re¯ect dierences in the lineages and cell lines analysed. In view of data revealing several of the small molecule inhibitors of the PI3K cascade to realize their inhibitory eects both in vitro and in vivo (Dumont and Su, 1996; Schultz et al., 1995; Shi et al., 1995; Vlahos et al., 1994) , the current data showing dierential sensitivity of PTEN-negative versus PTEN-positive cells to these inhibitors may be exploited therapeutically. This possibility is particularly relevant to treatment of breast cancers as the frequency of PTEN mutations in these cancers suggest that the development and progression of these tumors is signi®cantly in¯uenced by the PI3K pathway. Indeed, PTEN-de®cient breast cancer cells appear to be more sensitive to the eects of LY294002-mediated PI3K inhibition than were breast cancer cells with normal PTEN expression ( Figure  8) . Importantly, the involvement of the PI3K pathway in tumorigenesis may be realized by mechanisms other than mutation of the PTEN tumor suppressor gene. Thus, for example, we have recently demonstrated that ampli®cation of the p110a subunit of PI3K to be a frequent event in ovarian cancer and shown that the phenotypes of cells with mutant PTEN and ampli®ed PI3K are remarkably similar. Our data indicate that cells with either one of these genetic defects exhibit increased signaling through the PI3K pathway, resistance to apoptosis and increased sensitivity to LY294002 (Shayesteh et al., 1999) . Thus altered function of the PI3K pathway may be a frequent source of oncogenicity in multiple cell lineages and, as such, represents an attractive target for molecular therapeutics of cancer.
Materials and methods
Antibodies and reagents
Rabbit anti-PTEN has been described previously (Davies et al., 1998) . Goat anti-PTEN (N-terminal) and monoclonal antip27Kip1 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phospho-AKT, anti-phospho-BAD, and antiphospho-p70S6K were from New England Biolabs (Beverly, MA, USA). Sheep anti-phospho-GSK3a (Ser21), monoclonal anti-GSK3a/b and HRP-conjugated rabbit anti-sheep IgG were from Upstate Biotechnology (Lake Placid, NY, USA). Monoclonal anti-p21Cip1/Waf1 was from Transduction Laboratories (Lexington, KY, USA). Monoclonal anti-HA was from the mouse hybridoma 12CA5 (Dr Su, Houston, TX, USA). Monoclonal anti-FLAG (M2) and wortmannin were from Sigma (St. Louis, MO, USA). HRP-conjugated goat antirabbit IgG and HRP-conjugated goat anti-mouse IgG were from BioRad (Hercules, CA, USA). HRP-conjugated protein A was from Amersham (Arlington Height, IL, USA). Protein A or protein G conjugated sepharose 4B were from Pharmacia Biotech (Piscataway, NJ, USA). LY294002 was from Calbiochem (La Jolla, CA, USA).
Expression vectors and adenoviruses
FLAG epitope-tagged full-length wild-type PTEN and catalytic inactive PTEN (C124S) were from Drs Dixon and Maehama (Ann Arbor, MI, USA). The G129E (Gly129-Glu) PTEN mutation was generated by site-directed mutagenesis. HA-epitope tagged wild-type AKT was from Dr Downward (UK). AU-1 tagged wild-type BAD was from Dr Gabriel Nunez (Ann Arbor, MI, USA). The recombinant adenovirus containing wild-type PTEN (Ad-MMAC) and empty adenovirus (Ad-DE1) were described previously (Davies et al., 1998; Liu et al., 1999) .
Cell lines
Tumor cell lines were cultured in complete medium (RPMI 1640 supplemented with 10% FBS, and 2 mM L- MDA-MB-468 cells were infected with adenovirus and treated as described in Figure 6 . Per cent of cells distributed at various stages of cell cycle was measured and calculated by¯ow cytometry. Each treatment was performed in triplicate and presented as mean+s.e.m. (1 : 1) medium supplemented with 5% Equine Serum, Fungizone (0.5 mg/ml), Insulin (10 mg/ml), EGF (10 ng/ml), Cholera Endotoxin (100 ng/ml), Hydrocortisone (0.5 mg/ml) and CaCl 2 (1 mM).
Transient transfection and viral infection
Cells were transiently transfected with Fugene TM 6 Transfection Reagent (Boehringer Mannheim Inc., Indianapolis, IN, USA). For viral infection, cells were incubated with adenovirus at 25 MOI in a small volume of medium at 378C for 1 h and then changed to complete medium.
Cell lysis, immunoprecipitation and immunoblotting
Cells were washed twice with PBS and lysed in ice-cold lysis buer (1% Triton X-100, 50 mM HEPES, pH 7.4, 150 mM NaCl, 1.5 mM MgCl 2 , 1 mM EGTA, 100 mM NaF, 10 mM Na Pyrophosphate, 1 mM Na 3 VO 4 , 10% glycerol, 1 mM PMSF and 10 mg/ml aprotonin). Cellular protein concentration was determined by BCA reaction (Pierce, Rockford, IL, USA). For immunoprecipitation, detergent lysates were incubated with 1 mg of anti-HA monoclonal antibody or 8 mg of anti-FLAG (M2) for 90 min. Immune complexes were captured by protein A sepharose beads (anti-HA) or protein G sepharose beads (anti-Flag). Immunoprecipitates were washed with 0.5% Triton X-100, 0.5% NP-40, 10 mM Tris/HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM Na 3 VO 4 , 1 mM PMSF. Proteins were separated by SDS ± PAGE and transferred to polyvinylidene di¯uoride (PVDF) membranes. Membranes were blocked with 5% BSA and then incubated for 2 h at room temperature or overnight at 48C with anti-phospho-AKT (1 : 1000 dilution), AKT antibody (1 : 1000 dilution), anti-phospho-BAD Ser112 (1 : 1000 dilution), anti-BAD antibody (1 : 1000 dilution) or anti-phospho-BAD Ser136 antibody (1 : 500 dilution), anti-phospho-GSK3a (2 mg/ml), anti-GSK3a/b (0.5 mg/ml) antibody, anti-phospho-p70S6K (1 : 1000 dilution), antip70S6K (1 : 1000 dilution) antibody, anti-p27Kip1 mAb (1 mg/ml) or anti-p21Cip1/Waf1 mAb (1 : 500 dilution). Membranes were washed in TBS-T (10 mM Tris/HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20) and incubated with HRP-conjugated goat anti-mouse IgG or goat antirabbit IgG (1 : 2500 dilution) for 1 h at room temperature. Proteins were visualized by enhanced chemiluminescence detection (ECL, Amersham).
Cell growth assay
Cell growth was assessed by MTT (3,(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide) dye conversion at 570 nm as described (Hansen et al., 1989) . Brie¯y, cells were seeded in 96-well plates (¯at bottom, 5000 cells/well) and infected with adenovirus containing wild-type PTEN or empty virus (DE1). At each time point, 25 ml of MTT (5 mg/ ml in PBS) was added to each well. After 2 h incubation at 378C, cells were lysed by addition of 100 ml of 20% SDS in 50% DMF, pH 4.7.
Apoptosis and anoikis
Apoptosis and anoikis were measured using paraformaldehyde ®xed cells with an APO-BrdU kit (Phoenix Flow Systems, Inc., San Diego, CA, USA) or binding of PE conjugated Apo 2.7 (Coulter Immunotech, Hialeah, Florida, USA) with¯ow cytometry. At each time point, both BT-549 cells were infected with adenovirus expressing wild-type PTEN gene or empty virus (DE1) at 25 MOL. After infection, cells were cultured in the medium containing 0.5% or 10% of FBS for 48 h. Cells were harvested and ®xed by 1% paraformaldehyde. Cells were then processed and analysed for apoptosis using the PE conjugated Apo2.7 (Clone 2.7A6A3) monoclonal antibody (Coulter Immunotech) or APO-BrdU Kit (Phoenix Flow System, Inc, San Diego, CA, USA) as recomended by the manufacturer Figure 8 Breast cancer cells with mutant PTEN are more sensitive to growth inhibition by the PI3K inhibitor LY294002. Cells were cultured in 96-well plates (5000 cells/well) for 96 h in the presence or absence of LY294002 in medium containing 0.5% or 10% FBS. Cell number and viability were assayed by MTT dye conversion and presented as per cent inhibition [(OD570 without LY294002 ± OD570 with LY294002)/OD570 without LY2940026100] (Mean+s.e.m. for ®ve replicates) ¯oating and attached cells were collected and washed with PBS. For anoikis assays, cells were incubated on a rocker platform.
